Wednesday, July 15, 2026
7:00 p.m. – 8:00 p.m. ET
Please note this virtual program is at 7:00 p.m. Eastern, 6:00 p.m. Central, 5:00 p.m. Mountain and 4:00 p.m. Pacific.
FACULTY
 |
Daniel DeSalvo, MD Associate Professor Pediatric Diabetes & Endocrinology Baylor College of Medicine Texas Children’s Hospital Director of Strategic Collaboration Texas Children’s Diabetes Care Center Houston, Texas |
 |
Roshanak Monzavi, MD Clinical Professor of Pediatrics Director of Fellowship Program Center for Endocrinology, Diabetes, and Metabolism Children’s Hospital Los Angeles Los Angeles, California |
PROGRAM OVERVIEW
With the advent of disease-modifying therapies to delay progression of type 1 diabetes (T1D), as well as their potential application of these therapies in newly diagnosed T1D, there is an increased emphasis on presymptomatic screening, staging, and monitoring—representing a true paradigm shift in how we address the disease. This proactive approach is paramount in pediatric populations, who are at higher risk for progression after testing positive for islet autoantibodies. This symposium will provide an overview of the practical considerations for early detection of T1D and the application of disease-modifying therapy for delaying disease progression in pediatric patients, while also exploring emerging treatment approaches aimed at preserving beta cell function in newly diagnosed T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pediatric endocrinologists.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Implement risk-based screening approaches to facilitate timely identification of presymptomatic T1D
- Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
- Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
- Recognize the importance of beta-cell preservation on T1D prognosis and outcomes
- Review emerging approaches aimed at beta cell preservation & their potential future application in new-onset T1D
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 CPEU.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
